Salix says higher dose of bowel drug effective
June 18 (Reuters) - Salix Pharmaceuticals Ltd. (SLXP.O) reported positive results from a late-stage trial of a higher dose of its drug, Colazal, for the treatment of a bowel disease called ulcerative colitis.
The speciality pharmaceutical company expects to submit a new drug application for the 1100 mg dosage of Colazal by July 31.
Salix already markets Colazal, also known as balsalazide, in 750 mg strength.
(Reporting by Aniruddha Basu in Bangalore)
((Editing by Himani Sarkar; Reuters Messaging: aniruddha.basu@.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: SALIXPHARMACEUTICALS/ TRIAL
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS4114
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters